Dermatomyositis is caused by an abnormal immune response that attacks small blood vessels in the skin and muscles. The exact reason this happens varies from person to person, but it typically involves a combination of genetic vulnerability, an overactive immune pathway, and an environmental trigger such as sun exposure, a viral infection, or certain medications. In some adults, dermatomyositis develops as the body’s reaction to an underlying cancer.
The Core Problem: An Overactive Immune Pathway
At the cellular level, dermatomyositis is driven by a specific branch of the immune system called the type I interferon pathway. In healthy people, this pathway activates briefly to fight viruses and then quiets down. In dermatomyositis, it stays switched on. Genes associated with this pathway are highly active in affected muscle tissue, particularly in areas where muscle fibers have begun to shrink and weaken around the edges of fiber bundles.
Specialized immune cells called plasmacytoid dendritic cells, which are potent producers of interferons, accumulate in the muscles of people with dermatomyositis. These cells drive a cascade of inflammation that damages muscle fibers, skin cells, and the lining of small blood vessels. This is why dermatomyositis produces both a distinctive skin rash and progressive muscle weakness, often starting in the shoulders and hips.
Skin changes frequently appear first. Muscle weakness can show up at the same time as the rash, or it may follow weeks, months, or even years later. Some people develop the skin findings without ever experiencing significant muscle problems, a subtype called amyopathic dermatomyositis.
Genetic Susceptibility
Dermatomyositis is not directly inherited, but certain gene variants make a person more likely to develop it. The strongest associations involve genes in the HLA system, which helps the immune system distinguish the body’s own proteins from foreign invaders. Specific variants in a gene called HLA-DRB1 significantly increase the risk. One variant, DRB1*04:01, was found at a rate of 17% in patients with a particular autoantibody profile compared to just 1.3% in healthy controls, representing roughly a 16-fold increase in risk. Another variant, DRB1*12:02, appeared in about 43% of these same patients versus 19% of controls.
These genetic differences don’t guarantee someone will develop dermatomyositis. They influence which autoantibodies the immune system produces if the disease does develop, and those autoantibodies in turn shape how the disease behaves, including which organs are affected most.
Autoantibodies and What They Mean
Most people with dermatomyositis carry one of several autoantibodies, each linked to a distinct pattern of disease. These aren’t just diagnostic markers. They reflect different underlying immune processes and help explain why dermatomyositis looks so different from one patient to the next.
- Anti-Mi-2: The “classic” dermatomyositis antibody, associated with prominent skin rash and muscle weakness that generally responds well to treatment.
- Anti-TIF1-gamma (p155/140): Strongly linked to cancer-associated dermatomyositis in adults. A meta-analysis found this antibody has about 70% sensitivity and 89% specificity for identifying patients whose dermatomyositis is connected to a malignancy.
- Anti-MDA5: Found in patients with mild or absent muscle disease but frequently associated with rapidly progressive lung disease and distinctive skin ulcers on the hands, particularly the palms.
- Anti-Jo-1 and other synthetase antibodies: Associated with a cluster of features including lung disease, cracked and roughened skin on the hands (“mechanic’s hands”), joint inflammation, and Raynaud’s phenomenon.
Sun Exposure as a Trigger
Ultraviolet radiation is one of the best-documented environmental triggers for dermatomyositis. Intense sun exposure damages skin cells and DNA, producing cellular debris that the immune system may misidentify as a threat. UV light also increases reactive oxygen species and triggers the death of skin cells in ways that can expose normally hidden proteins to the immune system, potentially creating new targets for autoimmune attack. Sunburn itself is an acute inflammatory response that can amplify these effects.
This connection is strong enough that many people with dermatomyositis notice their skin symptoms flare after sun exposure, and sun protection is a standard part of managing the condition. Research using national patient registries has confirmed the association between UV radiation levels and dermatomyositis development.
Viral Infections
Several viruses have been proposed as triggers, with the theory being that a viral infection could activate the interferon pathway and, in genetically susceptible people, set off a self-sustaining autoimmune response. Influenza A and B, Coxsackieviruses, HIV, and HTLV-1 have all been linked to viral muscle inflammation. Parvovirus B19 attracted particular interest after a case in 2000 where the virus was detected directly in the muscle tissue of a dermatomyositis patient. However, a follow-up study testing seven additional dermatomyositis patients found no trace of parvovirus in any of their muscle biopsies, weakening the case for a direct viral cause.
The current thinking is that infections likely serve as triggers rather than ongoing causes. A virus may kick-start the immune process, but the autoimmune attack then sustains itself even after the infection clears.
The Cancer Connection
Dermatomyositis can develop as a paraneoplastic syndrome, meaning the immune system’s attempt to fight a hidden cancer inadvertently damages the body’s own muscle and skin tissue. In a large study published in the New England Journal of Medicine involving 392 dermatomyositis patients, 15% were diagnosed with cancer at the same time or after their dermatomyositis diagnosis. Broader estimates across different studies range from 6% to 60%, though the wide variation reflects differences in study size and patient populations at referral centers.
The risk is highest in the first one to three years after diagnosis, which is why adults newly diagnosed with dermatomyositis typically undergo cancer screening. The cancers most commonly involved include ovarian, lung, pancreatic, stomach, and colorectal cancers, though the specific types vary by population. The presence of anti-TIF1-gamma antibodies is a particularly strong signal that an underlying malignancy may be present. In some cases, treating the cancer leads to improvement in the dermatomyositis itself, further confirming the link.
This cancer association is largely an adult phenomenon. In children with dermatomyositis, malignancy is extremely rare.
Medications That Can Trigger Dermatomyositis
Certain drugs can provoke dermatomyositis by inducing abnormal immune reactions. A large analysis of the FDA’s adverse event reporting system identified 24 drugs with significant associations. Cardiovascular drugs, particularly statins, were the most frequently reported category, with atorvastatin, rosuvastatin, and simvastatin leading the list. Hydroxyurea showed the strongest statistical signal of any individual drug, followed by fenofibrate (a cholesterol-lowering medication) and atorvastatin.
Immune checkpoint inhibitors, a class of cancer immunotherapy drugs that work by releasing the brakes on the immune system, were the second most commonly implicated category. Other drug classes with documented associations include certain antibiotics (particularly tetracyclines like minocycline and doxycycline), platinum-based chemotherapy agents, disease-modifying antirheumatic drugs, and proton pump inhibitors such as omeprazole. Drug-induced dermatomyositis can sometimes resolve after the offending medication is stopped, though this is not guaranteed.
Juvenile Dermatomyositis
When dermatomyositis develops in children, the underlying immune mechanism is similar, with the same interferon-driven pathway and blood vessel inflammation at work. The triggers, however, may differ in emphasis. UV light exposure and emotional stress have both been reported as preceding events in juvenile cases, mirroring the adult triggers. One notable difference is that cancer-associated dermatomyositis is essentially absent in children. Infections in the weeks before onset are more commonly reported in juvenile cases, suggesting that developing immune systems may be particularly susceptible to infection-triggered autoimmunity. The genetic risk factors overlap with those seen in adults, reinforcing that juvenile and adult dermatomyositis are variations of the same disease rather than fundamentally different conditions.